{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:41:03Z","timestamp":1787312463773,"version":"build-2736575974"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>A Bayesian network meta-analysis was conducted to evaluate the efficacy, tolerability, and safety of vesicular monoamine transporter 2 (VMAT2) inhibitors in Huntington\u2019s disease chorea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were searched from January 1970 to January 2025 for eligible randomized controlled trials. Three VMAT2 inhibitors, including tetrabenazine, deutetrabenazine and valbenazine were investigated. The network meta-analysis was conducted based on a Bayesian framework using a fixed-effects model. As there were no closed loops in the network plot, comparisons of these interventions were directly formed by a consistency model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three randomized controlled trials (n = 299 patients) were included in the analysis. The surface under the cumulative ranking curve indicated that tetrabenazine was associated with the greatest improvement in the Unified Huntington\u2019s Disease Rating Scale Total Maximal Chorea score (0.878), followed by valbenazine (0.700) and deutetrabenazine (0.422). Meanwhile, in the Unified Huntington\u2019s Disease Rating Scale Total Motor score, valbenazine ranked highest, with a score of 0.781. Deutetrabenazine ranked highest in terms of overall withdrawals (0.800) and adverse events (AEs) (0.688), while valbenazine ranked first in withdrawals due to AEs (0.735), serious adverse events (0.807), as well as in reducing both suicide (0.683) and suicidal ideation (0.748).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study suggests that three VMAT2 inhibitors are effective in ameliorating chorea symptoms in patients with Huntington\u2019s disease. Tetrabenazine is the most effective in controlling chorea, whereas valbenazine may be the optimal choice for patients with comorbid psychiatric symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251012431<\/jats:ext-link>\n                      , identifier CRD420251012431.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1637577","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T05:41:27Z","timestamp":1758692487000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of vesicular monoamine transporter 2 inhibitors for Huntington\u2019s disease chorea based on network meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Jing","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei-Fei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yuan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Qing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3389\/fneur.2019.00710","article-title":"International guidelines for the treatment of Huntington\u2019s disease","volume":"10","author":"Bachoud-L\u00e9vi","year":"2019","journal-title":"Front. Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/cpdd.1205","article-title":"Pharmacokinetic and pharmacologic characterization of the dihydrotetrabenazine isomers of deutetrabenazine and valbenazine","volume":"12","author":"Brar","year":"2022","journal-title":"Pharmacol. Drug Dev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med. Decis. Mak."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s40263-022-00956-8","article-title":"The safety of deutetrabenazine for chorea in Huntington disease: an open-label extension study","volume":"36","author":"Frank","year":"2022","journal-title":"CNS Drugs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial","volume":"316","author":"Frank","year":"2016","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3109\/09540261.2013.825581","article-title":"Complexities of CYP2D6 gene analysis and interpretation","volume":"25","author":"Gaedigk","year":"2013","journal-title":"Int. Rev. Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/14656566.2021.1876666","article-title":"State-of-the-art pharmacological approaches to reduce chorea in Huntington\u2019s disease","volume":"22","author":"Gibson","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1124\/jpet.116.239160","article-title":"Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites","volume":"361","author":"Grigoriadis","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"555566","DOI":"10.19080\/GJPPS.2017.01.555566","article-title":"Deuteration as a tool for optimization of metabolic stability and toxicity of drugs","volume":"1","author":"Gupta","year":"2017","journal-title":"Glob. J. Pharm. Pharm. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/bs.pmch.2017.12.002","article-title":"VMAT2 inhibitors and the path to Ingrezza (valbenazine)","volume":"57","author":"Harriott","year":"2018","journal-title":"Prog. Med. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","year":"2006","journal-title":"Neurology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s13287-023-03518-x","article-title":"Efficacy and safety of mesenchymal stem cell therapy in liver cirrhosis: a systematic review and meta-analysis","volume":"14","author":"Lu","year":"2023","journal-title":"Stem Cell Res. Ther."},{"key":"B14","volume-title":"Ingrezza (valbenazine): prescribing information. Neurocrine Biosciences","year":"2022"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e1080","DOI":"10.1002\/cl2.1080","article-title":"CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst. Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/1060028018797110","article-title":"Impact of deuterium substitution on the pharmacokinetics of pharmaceuticals","volume":"53","author":"Russak","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s40268-017-0202-z","article-title":"Differences in dihydrotetrabenazine isomer concentrations following administration of tetrabenazine and valbenazine","volume":"17","author":"Skor","year":"2017","journal-title":"Drugs R. D."},{"key":"B19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S1474-4422(23)00127-8","article-title":"Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington\u2019s disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"22","author":"Stimming","year":"2023","journal-title":"Lancet Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/practneurol-2021-003074","article-title":"Huntington\u2019s disease: diagnosis and management","volume":"22","author":"Stoker","year":"2022","journal-title":"Pract. Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40271-018-0312-x","article-title":"Understanding how chorea affects health-related quality of life in Huntington disease: an online survey of patients and caregivers in the United States","volume":"11","author":"Thorley","year":"2018","journal-title":"Patient"},{"key":"B23","doi-asserted-by":"publisher","first-page":"115191","DOI":"10.1016\/j.jpba.2022.115191","article-title":"Determination of CYP450 activities in diabetes mellitus rats by a UHPLC-MS\/MS method","volume":"224","author":"Wang","year":"2023","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1637577\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T05:41:27Z","timestamp":1758692487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1637577\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":23,"alternative-id":["10.3389\/fphar.2025.1637577"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1637577","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"article-number":"1637577"}}